XtalPi Pushes 1.6 Million-Compound AI Platform for Molecular Glue Discovery
Updated
Updated · The National Law Review · May 22
XtalPi Pushes 1.6 Million-Compound AI Platform for Molecular Glue Discovery
1 articles · Updated · The National Law Review · May 22
Summary
XtalPi said its XGlue platform is shifting molecular glue discovery from chance findings to a design-led process, combining AI, physics-based modeling and robotic labs to predict and optimize ternary protein complexes.
1.6 million-plus virtual compounds and 5,000-plus diversity compounds feed an iterative screening pipeline that selects E3 ligase-target pairs, models binding and stability, and narrows candidates before synthesis.
600 compounds a week can be produced by automated synthesis systems, supported by more than 10,000 square meters of lab space and multi-cloud computing with million-peak CPU-core scheduling.
In a POI-X case study, XtalPi said optimization improved a hit from DC50 34 uM to 28 nM while reaching Dmax 79%, illustrating the platform's aim to tackle hard-to-drug targets with smaller, orally favorable molecular glues.
Can AI platforms like XGlue™ finally end the era of billion-dollar drug development failures?
As AI automates drug design, what is the new role for human scientific creativity?
If an AI-designed drug causes harm, who is legally responsible for the outcome?
AI, Automation, and XGlue™: XtalPi’s Blueprint for the Future of Molecular Glue Therapeutics in 2026
Overview
XtalPi's International Symposium on Molecular Glue Drug Discovery, held in 2026, marked a turning point for the pharmaceutical industry by bringing together top experts from academia and industry. The event acted as a catalyst, accelerating the molecular glue revolution and highlighting the field's potential to unlock new treatment pathways for diseases with unmet medical needs. Experts discussed how molecular glues work by inducing or stabilizing protein interactions that do not naturally occur, allowing them to target challenging diseases. This symposium signaled the dawn of a new era in therapeutics, emphasizing collaboration and innovation in drug discovery.